Fluzone


Also found in: Wikipedia.

Fluzone

(floo′zōn″)
Influenza virus vaccine, trivalent, types A and B.
References in periodicals archive ?
Influenza Vaccination Market Outlook 2019 to 2023 is latest research On Global Influenza Vaccination Market Report Analyzed By Type (Seasonal, Pandemic), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluzone, Flumist, Fluvirin, Fluvax), and End-Users (Hospitals, Research Organizations) - Forecast till 2023.
Other flu shots available are FLUAD, Fluzone HD and Flublok.
In addition, recent labeling changes for Afluria Quadrivalent and Fluzone Quadrivalent are addressed.
Volunteers will be randomly assigned to receive one dose of either the Fluzone Quadrivalent Influenza Vaccine or Flublok Quadrivalent Influenza Vaccine.
M2 PHARMA-January 24, 2019-Sanofi wins US FDA's approval for the 0.5 ml dose of Fluzone Quadrivalent influenza vaccine in children as young as six months
Global Banking News-January 24, 2019-Sanofi wins US FDA's approval for the 0.5 ml dose of Fluzone Quadrivalent influenza vaccine in children as young as six months
M2 EQUITYBITES-January 24, 2019-Sanofi wins US FDA's approval for the 0.5 ml dose of Fluzone Quadrivalent influenza vaccine in children as young as six months
Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to include children age 6 months through 35 months.
NanoFlu is a differentiated flu vaccine, as evidenced by superior hemagglutination inhibition antibody responses against wild-type A viruses, including drifted strains, when compared to Fluzone High-Dose, the leading flu vaccine in older adults.
Ask your doctor about getting the high-dose vaccine (Fluzone, which is aimed specifically at people age 65 and older).
Mercer presented findings from a phase IV randomized, observer-blinded study, in which the researchers assigned healthy children aged 6-35 months to receive Fluzone quadrivalent vaccine at a dose of 0.25 mL or 0.5 mL.
Mercer presented findings from a phase 4, randomized, observer-blinded study, in which the researchers assigned healthy children aged 6-35 months to receive Fluzone quadrivalent vaccine at a dose of 0.25 mL or 0.5 mL.